RTW Biotech Opportunities reports August NAV rise to $2.92 per share

RTW Biotech Opportunities Ltd (LSE: RTW) reported an unaudited net asset value (NAV) of $2.92 per ordinary share as of August 31, marking a 3.9% increase from the prior month. Over its lifetime since October 2019, the fund delivered an annualized NAV return of 15.7%, though it underperformed the Nasdaq Biotech Index (10.5% monthly) and the Russell 2000 Biotech Index (7.4%) in August alone. The fund’s holdings remain concentrated, with CG Oncology (CGON) at 7.5% of NAV, argenx (ARGX) at 6.1%, and Oruka (ORKA) at 5.2%. Notably, UroGen (URGN) contributed 5.0% to NAV year-to-date, while Ensoma detracted 1.7%. Recent transactions reshaped its portfolio and NAV: Obsidian Therapeutics, acquired on August 4 via a reverse merger with Galera Therapeutics, raised its carrying value by $2.5 million—a 2.5x return and 170% uplift based on its first-day Nasdaq listing at $34 per share. Concurrent private financing totaled approximately $350 million. On August 19, BioMarin Pharmaceutical announced a $490 million acquisition of Alesta Therapeutics, with an upfront payment of $275 million—a 41% uplift to RTW Bio’s July carrying value, adding $1.6 million to NAV. Over the past year, RTW Biotech repurchased 7.6 million shares for $14.7 million, reducing its discount to NAV from 28.9% to 13.8%. The fund’s recent activity underscores strategic investments in high-growth biotech assets, while its share buybacks reflect efforts to align shareholder value with NAV.